A retrospective investigation on the phenotype and stability of the E-protein gene in Japanese Encephalitis (JE) virus strain SA14-14-2 used live-attenuated JE vaccine

To detect retrospectively the phenotype and stability of the E-protein gene in Japanese Encephalitis (JE) virus strain SA14-14-2 used in the live-attenuated JE vaccine prepared at different years, the viral titer was titrated by plaque formation in BHK-21 cell cultures, and the neuro-virulence of viruses was assayed in mice with body weight of 12-14 g by intracerebral inoculation. Meanwhile, the total RNA of virus gene was extracted and amplified by RT-PCR with the designed primers, and then it was purified and cloned to the expression vector pGEM-T. The recombinant plasmid was purified and sequenced. It was found that the loss of viral titer of vaccines stored in -20℃ for longer than 10 years was less than 0.5 Lg PFU/ml. No mice inoculated intracerebrally showed signs of illness or even death. The size of plagues of the vaccine virus remained to be small, and the E genes of primary virus seed SA14-14-2 and the vaccines prepared at different years (1987-2001) were unchanged, including the 8 critical amino acid sites which were different from the parent wild virus strain SA14 and the related neuro-virulence. These results indicate that the genotypic and biological characteristics of the attenuated JE virus strain SA14-14-2 and its vaccines prepared are quite stable without any reversion noted.

Protective efficacy of an H5/H7 trivalent inactivated vaccine produced from Re-11, Re-12, and H7-Re2 strains against challenge with different H5 and H7 viruses in chickens

We developed an H5/H7 trivalent inactivated vaccine by using Re-11, Re-12, and H7-Re2 vaccine seed viruses, which were generated by reverse genetics and derived their HA genes from A/duck/Guizhou/S4184/2017(H5N6) (DK/GZ/S4184/17) (a clade 2.3.4.4d virus), A/chicken/Liaoning/SD007/2017(H5N1) (CK/LN/SD007/17) (a clade 2.3.2.1d virus), and A/chicken/ Guangxi/SD098/2017(H7N9) (CK/GX/SD098/17), respectively. The protective efficacy of this novel vaccine and that of the recently used H5/H7 bivalent inactivated vaccine against different H5 and H7N9 viruses was evaluated in chickens. We found that the H5/H7 bivalent vaccine provided solid protection against the H7N9 virus CK/GX/SD098/17, but only 50–60% protection against different H5 viruses. In contrast, the novel H5/H7 trivalent vaccine provided complete protection against the H5 and H7 viruses tested. Our study underscores the importance of timely updating of vaccines for avian influenza control.

Protective efficacy of an H5/H7 trivalent inactivated vaccine(H5-Re13,H5-Re14, and H7-Re4 strains) in chickens, ducks, and geese against newly detected H5N1, H5N6, H5N8, and H7N9 viruses

Some H5 viruses isolated in poultry or wild birds between 2020 and 2021 were found to be antigenically different from the vaccine strains(H5-Re11 and H5-Re12) used in China. In this study, we generated three new recombinant vaccine seed viruses by using reverse genetics and used them for vaccine production. The vaccine strain H5-Re13 contains the hemagglutinin(HA) and neuraminidase(NA) genes of an H5 N6 virus that bears the clade 2.3.4.4 h HA gene, H5-Re14 contains the HA and NA genes of an H5 N8 virus that bears the clade 2.3.4.4 b HA gene, and H7-Re4 contains the HA and NA genes of H7 N9 virus detected in 2021. We evaluated the protective efficacy of the novel H5/H7 trivalent inactivated vaccine in chickens, ducks, and geese. The inactivated vaccine was immunogenic and induced substantial antibody responses in the birds tested. Three weeks after vaccination, chickens were challenged with five different viruses detected in 2020 and 2021: three viruses(an H5 N1 virus, an H5 N6 virus, and an H5 N8 virus) bearing the clade 2.3.4.4 b HA gene, an H5 N6 virus bearing the clade 2.3.4.4 h HA gene, and an H7 N9 virus. All of the control birds shed high titers of virus and died within 4 days post-challenge, whereas the vaccinated chickens were completely protected from these viruses. Similar protective efficacy against H5 viruses bearing the clade 2.3.4.4 h or 2.3.4.4 b HA gene was observed in ducks and geese. Our study indicates that the newly updated H5/H7 vaccine can provide solid protection against the H5 and H7 N9 viruses that are currently circulating in nature.

H5N1 Avian Influenza Pre-pandemic Vaccine Strains in China

Objective To prepare the 4 candidate vaccine strains of H5N1 avian influenza virus isolated in China Methods Recombinant viruses were rescued using reverse genetics. Neuraminidase （NA） and hemagglutinin （HA） segments of the A/Xinjiang/1/2006, A/Guangxi/1/2009, A/Hubei/1/2010, and A/Guangdong/1/2011 viruses were amplified by RT-PCR. Multibasic amino acid cleavage site of HA was removed and ligated into the pCIpoll vector for virus rescue. The recombinant viruses were evaluated by trypsin dependent assays. Their embnjonate survival and antigenicity were compared with those of the respective wild-type viruses. Results The 4 recombinant viruses showed similar antigenicity compared with wild-type viruses, chicken embryo survival and trypsin-dependent characteristics. Conclusion The 4 recombinant viruses rescued using reverse genetics meet the criteria for classification of low pathogenic avian influenza strains, thus supporting the use of them for the development of seeds and production of pre-pandemic vaccines.

Agranulocytosis following injection of inactivated Japanese encephalitis vaccine(Vero cell):A case report

BACKGROUND Japanese encephalitis virus(JEV),a mosquito borne flavivirus,is the leading cause of viral encephalitis in Asia,in terms of frequency and severity.JEV infection is thought to confer lifelong immunity.With the near eradication of poliomyelitis,JEV is now the continent’s leading cause of childhood viral neurologic infection and disability.The most common clinical manifestation of JEV infection is acute encephalitis,and currently there is no specific antiviral therapy.Japanese Encephalitis Vaccine(JE-VC)is an effective prevention measure,including JE-VC,Live(JE-MB),and Inactivated JE-VC.CASE SUMMARY A 9-mo-old girl received injection of Inactivated JE-VC(Vero cell)(Liaoning Chengda,batch number 201611B17)on August 31,2017.On that night,she developed a fever with the body temperature up to 38.5°C,for which Ibuprofen Suspension Drops 1.25 mL was given as antipyretic treatment.On September 1,the patient developed apocleisis,and her parents noticed herpes in her oral cavity.The patient was sent to our hospital on September 3.Physical examination led to a diagnosis of herpetic stomatitis,for which Stomatitis Spray 1 puff,tid,Kangfuxin Liquid 2 mL,tid,and vitamin B20.5 tablet,tid,were prescribed.Routine blood tests for low fever on September 6,2017 revealed an absolute neutrophil count(ANC)of 0.62×109/L,hemoglobin(Hb)of 109 g/L,and platelet count(PLT)of 308×10^(12)/L,and the tests were monitored regularly thereafter.The patient was followed until July 26,2020,when routine blood tests revealed ANC 1.72×109/L,Hb 138 g/L,and PLT 309×1012/L,indicating that the neutropenia count had normalized.CONCLUSION This report attempts to bring to clinical attention that Inactivated JE-VC(Vero cell)might cause prolonged granulocytopenia or even agranulocytosis.

A Natural Vaccine Candidate Strain Against Cholera

E1 Tor Vibrio cholerae (EVC) strains may be classifled into two kinds-epidemigenic (EEVC) strains and non-epidemigenic (NEEVC) strains-based on a phage-biotyping system. A large number of EEVC strains have been screened for toxigenic and putative colonization attributes. One such naturally occurring strain (designated IEM 101) has been found which is devoid of genes encoding cholera toxin (CT), accessory cholera enterotoxin (ACE), zonula occludens toxin (ZOT), but possesses RS1 sequences and toxin-coregulated pilus A gene (tcpA) although tcpA is poorly expressed. It expresses type B pili but does not posses type C pili. It is an E1 Tor Ogawa strain and does not cause fluid accumulation in rabbit ileal loop tests. Active immunization of rabbits with strain IEM 101 elicited good protection against challenge with virulent strains of V cholerae O1. Oral administrationcaused no side effects in 15 human volunteers, colonized the gut for four to ten days and elicited good immune responses

The Lapinized Chinese Strain Vaccine Against Classical Swine Fever Virus:A Retrospective Review Spanning Half A Century

Classical swine fever （CSF）, a list A disease of Office International des Epizooties, is caused by classical swine fever virus （CSFV） belonging to the Flaviviridae family. The well-known lapinized Chinese strain of CSFV, also known as C-strain, was developed in China in the mid-1950s. In the past half a century, the vaccine has been proved to be safe and immunogenic in pigs of essentially any age. It is of high efficacy, providing immunized animals with broad-spectrum, sometimes lifelong, protection, which is contributed by both cell-mediated immunity and humoral immunity, against essentially all genotypes or subgenotypes of the virus. The maternal antibodies derived from immunized sows can confer solid protection of their offspring from disease; however, they have been proved to inhibit the successful active immunization of C-strain vaccine. The complete genomes of C-strain and dozens of established or field strains have been sequenced and annotated. Recently, the reverse genetics system of C-strain has been developed, resulting in several C- strain-derived candidate marker vaccines. Many countries manage to control or even eradicate CSF with the aid of mass vaccination with C-strain. in spite of these efforts, the eradication of the disease worldwide remains a big challenge and needs to go a long way, and provably still resorts to genetically modified C-strain vaccine. The authors present an overview of the characteristics of the vaccine, which has stood the test of half a century.

Effect of Attenuated Highly Pathogenic Pig Reproductive and Respiratory Syndrome(HP-PRRS) TJM-F92 Strain Vaccine on Immune Antibody Levels against Classical Swine Fever(CSF) and Foot-and-Mouth Disease(FMD)

Effects of attenuated highly pathogenic pig reproductive and respiratory syndrome（HP-PRRS）TJM-F92 strain vaccine on immune antibody level against classical swine fever（CSF）and foot-and-mouth disease（FMD）were studied from October 8 to November 12 in 2014,in order to optimize vaccination program of CSF,HP-PRRS and FMD and to provide scientific guidance for animal disease control and prevention work.The results showed that attenuated HP-PRRS（TJMF92 strain）vaccine had no significant effect on immune antibody level of hog cholera lapinized virus（HCLV,ST passage cell vaccine）attenuated vaccine and FMD-O inactivated vaccines（OZK/93 strain）,and single or combined use of three vaccines received good immunization effects.

Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management

Tick-borne encephalitis is an infection of central nervous system caused by tick-borne encephalitis virus transmitted to humans predominantly by tick bites. During the last few decades the incidence of the disease has been increasing and poses a growing health problem in almost all endemic European and Asian countries. Most cases occur during the highest period of tick activity, in Central Europe mainly from April to November. Tickborne encephalitis is more common in adults than in children. Clinical spectrum of the disease ranges from mild meningitis to severe meningoencephalitis with or without paralysis. Rare clinical manifestations are an abortive form of the disease and a chronic progressive form. A post-encephalitic syndrome, causing long-lasting morbidity that often affects the quality of life develops in up to 50% of patients after acute tick-borne encephalitis. Clinical course and outcome vary by subtype of tick-borne encephalitis virus(the disease caused by the European subtype has milder course and better outcome than the disease caused by Siberian and Far-Easter subtypes), age of patients(increasing age is associated with less favorable outcome), and host genetic factors. Since clinical features and laboratory results of blood and cerebrospinal fluid are nonspecific, the diagnosis must be confirmed by microbiologic findings. The routine laboratory confirmation of the tick-borne encephalitis virus infection is based mainly on the detection of specific Ig M and Ig G antibodies in serum(and cerebrospinal fluid), usually by enzyme-linked immunosorbent assay. There is no specific antiviral treatment for tick-borne encephalitis. Vaccination can effectively prevent the disease and is indicated for persons living in or visiting tick-borne encephalitis endemic areas.

Epidemiological Characteristics of Japanese Encephalitis in Guizhou Province,China,1971-2009

Objective The aim of the study was to establish the contemporary epidemiological characteristics of Japanese encephalitis （JE） in Guizhou Province. Methods A retrospective study of National Notifiable Disease Reporting System （NNDRS） data from 2971 through 2009, was conducted to ascertain the geographical, seasonal, and age distributions of JE incidence in Guizhou Province, China. Results A total of 68 425 JE cases were reported in Guizhou from 1971-2009. The JE cases occurred sporadically in all 9 prefectures of Guizhou, mostly among residents of rural areas. Seasonal distribution of JE remained consistent over the period from 1971-2009 with the main transmission season starting from June to September and peaking in August. JE occurred mainly in children under the age of 15 years with peak incidence in the 0-6-year age group. Pearson＇s correlation analysis showed that JE vaccine distribution had a negative correlation with JE incidence rates during 1971-2009 （coefficient of correlation=-0.475, P〈O.01）. Conclusion Over the period of 1971-2009, the JE incidence rate had declined dramatically in terms of geographical and age distributions due to JE vaccination to children at risk.

Antibody Dynamic Changes in SPF Chickens and SPF Ducks Immuned with Recombinant Avian Influenza Virus H5 Subtype Bivalent Inactivated Vaccine

To study the immune effect of recombinant avian influenza virus H5 subtype bivalent inactivated vaccine （ HSN1, Re-6 strain ＋ Re-4 strain） and to provide the basis for formulating reasonable immune procedure of avian influenza vaccine in clinical practice. A total of 12 batches of vaccines from three companies were used for the iannune of SPF chickens and SPF ducks. Each chicken or duck serum was separately collected every 3 weeks until the immunization up to the 24^th week. The serum antibody titers of Re-6 and Re-4 were detected. The results showed that the HI titers of the inoculated SPF chickens and SPF ducks roached the peak when the immune time were the 6^th and 3^rd week after the first immunization respectively; then the titer decreased gradually as time prolonged; the highest titer of SPF chickens was greater than that of SPF ducks; the high titer duration of SPF chickens were longer than that of SPF ducks ; and all the vaccines from the three companies showed a good immune effect.

Safety and Antibody Responses to Aerosolized MMR II Vaccine in Adults: An Exploratory Study

Background: There have been no reported studies involving aerosol immunization with 2 of the 3 components of MMR II vaccine—Attenuvax measles vaccine and Jeryl-Lyn mumps vaccine. Objective: To evaluate the safety and antibody responses to aerosolized Attenuvax measles strain, Jeryl Lynn mumps strain and RA 27/3 rubella component of an MMR vaccine in adults, before assessing the booster administration of this vaccine in children. Methods: A pilot study to evaluate safety and antibody responses of MMR II (Merch Sharp & Dhome Corp., Whitehouse Station, NJ 08889, USA) components administered by aerosol was carried out in 27 healthy adults of 21 to 38 years of age. All participants were followed-up during 28 days following immunization for detection of clinical adverse events. Immune response was evaluated by plaque reduction neutralization test for measles, and commercial ELISA kits for rubella and mumps. Results: Only mild clinical adverse events were noted. Despite high levels of baseline seropositivity to all vaccine components, seroresponses to measles, rubella and mumps occurred in 44%, 15% and 41%, respectively. Conclusions: These outcomes compare favorably with earlier studies of other MMR vaccines given by aerosol. Further evaluations on safety and booster immune response should be performed in children.

Genetically engineered bacterial-like particles induced specific cellular and humoral immunity as effective tick-borne encephalitis virus vaccine

Tick-borne encephalitis(TBE)is a natural focal disease with fatal encephalitis induced by tick-borne encephalitis virus(TBEV),seriously threatening human and public health.Protection of TBE depends on vaccination with inactivated vaccine,which requires high cost and multiple immunizations.Here,we construct genetically engineered bacterial-like particles(BLPs)as an effective TBEV vaccine with simplified immunizations and improved immune efficacy.The TBEV BLPs involve the combination of the gram-positive enhancer matrix from Lactococcus lactis,and TBEV envelope(E)protein expressed by genetically engineered recombinant baculovirus.The prepared TBEV BLPs can effectively stimulate the activation of dendritic cells to present the TBEV E proteins to T and B cells,leading to strong and durable cellular and humoral immune responses in mice.Surprisingly,the serum levels of specific IgG antibodies in mice remain about 10^(6)at 6 months after the secondary immunization.Overall,the TBEV BLPs can be used as a potent vaccine candidate,laying the foundation for developing novel TBEV genetically engineered vaccines.

Development of a novel virus-like particle-based vaccine for preventing tick-borne encephalitis virus infection

Tick-borne encephalitis virus(TBEV)is an important tick-borne pathogen that poses as a serious public health concern.The coverage and immunogenicity of the currently available vaccines against TBEV are relatively low;therefore,it is crucial to develop novel and effective vaccines against TBEV.The present study describes a novel strategy for the assembly of virus-like particles(VLPs)by co-expressing the structural(core/prM/E)and non-structural(NS2B/NS3Pro)proteins of TBEV.The efficacy of the VLPs was subsequently evaluated in C57BL/6 mice,and the resultant IgG serum could neutralize both Far-Eastern and European subtypes of TBEV.These findings indicated that the VLP-based vaccine elicited the production of cross-subtype reactive antibodies.The VLPs provided protection to mice lacking the type I interferon receptor(IFNAR^(-/-))against lethal TBEV challenge,with undetectable viral load in brain and intestinal tissues.Furthermore,the group that received the VLP vaccine did not exhibit significant pathological changes and the inflammatory factors were significantly suppressed compared to the control group.Immunization with the VLP vaccine induced the production of multiple-cytokine-producing antiviral CD4+T cells in vivo,including TNF-α^(+),IL-2^(+),and IFN-γ^(+)T cells.Altogether,the findings suggest that noninfectious VLPs can serve as a potentially safe and effective vaccine candidate against diverse subtypes of TBEV.

越南非洲猪瘟疫苗AVAC ASF LIVE(ASFV-G-ΔMGF)研究工作分析与思考

非洲猪瘟(Afcrian swine fever,ASF)是由非洲猪瘟病毒(African swine fever virus,ASFV)感染引起的烈性传染病。近日,越南正式将经临床试验验证的非洲猪瘟弱毒疫苗AVAC ASF LIVE(ASFV-G-ΔMGF)在其全国推广使用。本文对越南非洲猪瘟弱毒疫苗ASFV-G-ΔMGF相关研究数据进行了总结分析,分别从ASFVG-ΔMGF株攻毒保护能力评价、传代细胞培养株临床动物实验、野猪口服接种试验、毒力返强验证等方面,结合国内相关ASFV基因缺失株试验数据进行了分析。总结分析发现:越南上市的ASFV-G-ΔMGF疫苗株,二次免疫接种后攻毒保护效果更好,但在对野猪的口服接种评价中,其口鼻接种效果存在不确定性;随着疫苗株在动物体内的不断传代,其存在毒力返强和毒株变异风险,导致接种猪只临床症状明显;ASFV-G-ΔMGF株虽然有较好的攻毒保护能力和可靠的生产优势,但仍缺乏相关研究数据,特别是在垂直传播、交叉保护、基因突变等方面。后续仍需对ASFV-G-ΔMGF株的临床应用效果进一步评价。

猴痘病毒感染的神经系统表现研究进展

在过去的一年内,猴痘的爆发已成为全球关注的问题。猴痘是猴痘病毒感染引起的人畜共患病,除典型的皮疹症状以外,猴痘病毒感染还可引起一系列神经系统表现,潜在的机制可能包括感染后免疫介导的神经系统损伤,以及病毒直接侵入神经系统。本文围绕猴痘病毒感染的神经系统表现进行综述,以促进早期识别、诊断猴痘病毒感染神经系统并发症,及时采取相应的防治措施。

维氏气单胞菌弱毒株FS12001及其疫苗对异育银鲫的免疫效果

为探究由维氏气单胞菌(Av)弱毒株FS12001制备的疫苗免疫效果,将Av弱毒株FS12001制备活疫苗、灭活疫苗、ISA763A-灭活疫苗和蜂胶-灭活疫苗,腹腔注射免疫异育银鲫,同时设ISA763A佐剂、蜂胶佐剂及0.65%NaCl作为对照组。于免疫后1、3、5、7和14 d经实时荧光定量PCR(qRT-PCR)检测脾脏组织中IgM、IL-1β及LZM的基因表达量;于免疫后7、14、21、28、42和48 d尾静脉采血分离血清,检测IgM抗体水平,测定SOD和LZM酶活性;于免疫28 d后用2株Av强毒株分别攻毒各组实验鱼,连续观察记录7 d,计算各免疫组的相对保护率。结果显示,各免疫组脾脏组织中IgM、IL-1β及LZM的基因表达量高于对照组,且ISA763A-灭活疫苗组和蜂胶-灭活疫苗组的表达量显著高于其他各实验组。各疫苗免疫组血清特异性抗体水平均显著高于0.65%NaCl对照组和佐剂对照组。各疫苗免疫组的LZM活性均在28 d最高,灭活疫苗组、ISA763A-灭活疫苗组及蜂胶-灭活疫苗组SOD活性均在7 d最高。菌株AVCA07攻毒后,活疫苗组、灭活疫苗组、ISA763A-灭活疫苗组和蜂胶-灭活疫苗组的RPS分别为63%、56%、100%和56%;菌株YC170511攻毒后,以上4个免疫组RPS分别为59%、55%、93%和72%。研究表明,用弱毒株FS12001制备疫苗,注射免疫异育银鲫后均可增加脾脏中IgM、IL-1β及LZM的基因表达量,提高血清抗体水平,增强SOD和LZM酶活性,增强其抵抗Av感染的能力。

Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses

Objective To explore on the immunity of live attenuated Japanese Encephalitis (JE) vaccine (SA14-14-2) to different wild JE virus (JEV) strains.Methods The neutralizing effect of the vaccine against different wild JE virus strains was detected by plaque reduction neutralization test ( PRNT), and the immunogenicity was studied on mice by vaccination - challenge protection test. In the PRNT , pooled sera from vaccinated human were tested against 10 strains of JEV , one isolated in Taiwan and 9 from other Asian countries. In the vaccination challenge test, mice received one dose of the live vaccine subcutaneously and were challenged intraperitoneally 14 days later against 22 JEV virus strains, 11 were isolated in China and the other 11 from Tailand, Vietnahailam, Indonesia, India, Philippines and Japan.Results The protection rates to all the 22 challenge virus were 90% -100% when 340 PFU/0.1 ml vaccinate virus was administered. The neutralizing effect showed that all the JEV isolates many have neutralized by the sera.Conclusion SA14-14-2 live attenuated prepared with strain SA14-14-2 is broadly immunogenic and mav have effective protection against in Asian JE affected countries.

鸡胚免疫新城疫疫苗后宿主法氏囊转录组学分析

【目的】通过转录组学分析鸡胚免疫新城疫病毒(Newcastle disease virus,NDV)TS09-C株后宿主法氏囊内免疫关键基因及信号通路分子转录差异,探究免疫后宿主法氏囊内免疫相关分子的调控反应。【方法】将60只18胚龄SPF鸡胚随机分为免疫组和对照组,30枚/组,免疫组将NDV TS09-C株通过羊膜腔接种鸡胚,剂量为103.0 EID 50/枚,注射体积为0.1 mL,对照组以同样的方法接种等体积PBS。检测免疫后不同时间点肺脏、胸腺、脾脏和法氏囊组织的病毒载量。选取病毒载量最高的法氏囊组织进行转录组学测序后,筛选免疫相关差异表达基因并分析其参与的主要功能及通路。【结果】免疫后1 d法氏囊组织中即可监测到病毒,免疫后3 d病毒载量达到最高。将免疫后3 d的法氏囊进行转录组学分析,与对照组相比,免疫组有453个基因上调、98个基因下调,其中免疫相关基因有36个上调、10个下调。免疫相关差异表达基因主要富集于自噬和细胞因子-细胞因子受体相互作用的免疫相关通路。差异表达基因蛋白互作分析显示,自噬通路中富集的BCL2与其他免疫相关基因有较多互作关系,且在B细胞活化、分化、免疫系统发育等功能注释中均有参与。【结论】本研究结果揭示了鸡胚免疫NDV TS09-C株后法氏囊内调控B细胞活化、分化的潜在靶向基因及通路,为进一步研究该毒株鸡胚免疫后B淋巴细胞调控的分子机制提供新的信息。

新流腺三联灭活疫苗对禽流感病毒和禽腺病毒流行株攻毒的免疫保护试验

为了验证鸡新城疫、禽流感(H9亚型)、禽腺病毒病(Ⅰ群,4型)三联灭活疫苗对H9亚型禽流感、禽腺病毒(Ⅰ群,4型)流行毒株的免疫保护效果,采用三联灭活疫苗免疫3周龄SPF鸡,免疫后21 d采血测定禽流感H9亚型HI抗体效价,同时分别用H9亚型禽流感病毒YT株、HD株、CX株和DL株以及禽腺病毒(Ⅰ群,4型)QD株、NJ株、HA株和CZ株进行攻毒,观察疫苗对H9亚型禽流感及禽腺病毒(Ⅰ群,4型)流行毒株的免疫保护效果。结果显示,免疫组禽流感H9亚型HI抗体效价几何平均值为1∶676~1∶832,对照组试验鸡HI抗体均<1∶2;用H9亚型禽流感病毒YT株、HD株、CX株和DL株攻毒,对照组鸡9/10~10/10发病,免疫组鸡均9/10以上保护;用禽腺病毒(Ⅰ群,4型)QD株、NJ株、HA株和CZ株攻毒,对照组鸡9/10~10/10发病,免疫组鸡均10/10保护。表明新流腺三联灭活疫苗对2020-2022年分离的H9亚型禽流感病毒及禽腺病毒(Ⅰ群,4型)流行毒株感染具有良好的免疫保护效果。